AI Summary
✦ ClarthaThyrocare Technologies is an Indian diagnostic testing company serving patients, laboratories, and hospitals. Diagnostic Testing Services drives pathology revenue through collection consumables and promotional activities. Imaging Services contributes radio-pharmaceutical and reporting consumables, while Others sells Sugarscan glucometers and glucostrips. Consolidated June 2026 sales rose 24.3% year-on-year, extending the recent 20.7% revenue growth rate. Profit increased 78.2% year-on-year, alongside improving margins, but ROE is unavailable for assessment. Debt-to-equity of 8.65 indicates substantial leverage, which can amplify reported ROE but increases financial risk. At 54.6 times earnings, the shares appear overvalued relative to current growth, despite recent sales acceleration. The key investor question is whether margin improvement can persist while leverage remains elevated.
Valuation Metrics
Trading 115.8% above historical median. Valuation is rising — currently in the strongly overvalued zone (z-score: +2.69). Confidence: 63%.
Live forward EPS implies next-12-month EPS of ₹15.86. Applying the stock's normalized valuation corridor produces a fair range of ₹289.76 to ₹574.29, with base value near ₹414.10 (-33.4% vs current price).
Live forward estimate anchored to the company's historical valuation corridor.
Forward EPS
₹15.86
Forward P/E
39.2x
Base Fair Value
₹414.10
Fair Range
₹289.76 - ₹574.29
Upside To Base
-33.4%
Estimate Source
Live forward EPS
Growth Estimate
+31.8%
5Y Average
25.45
Current
56.35
Overvalued
36.21
Undervalued
18.27
5Y Average
16.87
Current
37.36
Overvalued
20.49
Undervalued
11.48
5Y Average
5.10
Current
11.30
Overvalued
6.20
Undervalued
3.47
Peers & Comparison
Sector: Health Care · Theme: Hospitals & Diagnostic Centres
| Company | Rev. Growth | Margin | P/E | vs Avg | 52W Perf. |
|---|---|---|---|---|---|
RAINBOW CHILDRENS MED LTD RAINBOWHospitals & Diagnostic Centres | +33.2% | 15.7% | 54.6x Undervalued | -24% vs avg | +3.5% |
PARK MEDI WORLD LIMITED PARKHOSPSHospitals & Diagnostic Centres | +19.3% | 16.1% | 44.1x Undervalued | -39% vs avg | +97.5% |
METROPOLIS HEALTHCARE LTD METROPOLISHospitals & Diagnostic Centres | +16.6% | 11.8% | 58.8x Undervalued | -18% vs avg | +10.2% |
JUPITER LIFE LINE HOSP L JLHLHospitals & Diagnostic Centres | +18.2% | 12.0% | 55.8x Undervalued | -23% vs avg | +11.3% |
NEPHROCARE HEALTH SERV L NEPHROPLUSHospitals & Diagnostic Centres | +21.2% | 7.7% | 85.9x Premium | +19% vs avg | +47.3% |
NARAYANA HRUDAYALAYA LTD. NHHospitals & Diagnostic Centres | +80.4% | 9.0% | 45.3x Undervalued | -37% vs avg | +6.8% |
GLOBAL HEALTH LIMITED MEDANTAHospitals & Diagnostic Centres | +26.5% | 11.9% | 71.4x Fair | -1% vs avg | +4.9% |
KRISHNA INST OF MED SCI L KIMSHospitals & Diagnostic Centres | +35.3% | 4.8% | 160.4x Premium | +123% vs avg | +11.6% |
THYROCARE TECH LTD trades at a discount (56.3x vs peer avg 72.0x), suggesting potential undervaluation relative to the Hospitals & Diagnostic Centres cohort. Peers include RAINBOW CHILDRENS MED LTD, PARK MEDI WORLD LIMITED, METROPOLIS HEALTHCARE LTD — selected based on business model, industry classification, market cap similarity, and business theme alignment.
Financials
Real statement data for revenue, earnings quality, conversion, and balance-sheet coverage. Monetary values are shown in Rs crore.
Latest revenue
₹182 CrDec 2025Latest net profit
₹32 CrDec 2025Latest EPS
₹1.64Dec 2025Net margin
21.2%Dec 2025Performance
Bars show revenue and net profit. The line shows net margin.
- Revenue
- Net income
- Net margin %
Earnings
Revenue is shown in crores. EPS is rupees per share.
- Revenue
- EPS
Revenue to profit conversion
Bridge from operating numbers to profit for the latest reported period.
Latest reported period: Dec 2025
Debt level and coverage
Debt, cash and free cash flow compared on the same crore scale.
- Debt
- Free cash flow
- Cash & equivalents
Results
| Metric | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 125 | 124 | 136 | 123 | 141 | 144 | 163 | 153 | 174 | 179 | 202 | 182 |
| Expenses | 102 | 90.49 | 99.66 | 92.36 | 108 | 101 | 114 | 112 | 118 | 122 | 133 | 124 |
| Operating Profit | 13.35 | 24.61 | 27.33 | 19.63 | 23.18 | 32.9 | 38.85 | 24.91 | 43.86 | 47.57 | 59.21 | 38.69 |
| OPM % | 10.7% | 19.91% | 20.05% | 15.97% | 16.41% | 22.91% | 23.83% | 16.33% | 25.23% | 26.59% | 29.28% | 21.2% |
| Other Income | 2.07 | 0.46 | 1.82 | 2.09 | 2.81 | 3.17 | 2.12 | 3.51 | 4.54 | 3.96 | 2.28 | 3.9 |
| Interest | 0.6 | 0.8 | 1.02 | 0.96 | 0.94 | 0.93 | 0.63 | 0.48 | 0.6 | 0.62 | 0.6 | — |
| Depreciation | 9.42 | 8.51 | 9.3 | 10.9 | 10.41 | 9.45 | 9.94 | 15.34 | 11.78 | 8.95 | 9.7 | 19.58 |
| Profit before tax | 14.82 | 24.27 | 28.13 | 20.76 | 25.05 | 35.14 | 40.34 | 27.94 | 47.8 | 50.91 | 60.89 | 42.59 |
| Tax % | 33% | 31.07% | 27.87% | 28.28% | 23.23% | 28.43% | 26.65% | 31.64% | 54.08% | 29.19% | 29.33% | 24.58% |
| Net Profit | 9.93 | 16.73 | 20.29 | 14.89 | 19.23 | 25.15 | 29.59 | 19.1 | 21.95 | 36.05 | 43.03 | 32.12 |
| EPS in Rs | 1.88 | 3.16 | 3.83 | 2.81 | 3.63 | 4.75 | 5.59 | 3.53 | 4.08 | 6.80 | 8.12 | 1.64 |
All values in Rs. Crore unless otherwise stated. Source: CMIE Prowess, Quarterly Interim Standalone.